Related Experiment Videos
Platelet--arterial synthetic graft interaction and its modification
Archives of Surgery (Chicago, Ill. : 1960)
|November 1, 1982
Summary
Dacron grafts show high platelet reactivity in vivo, unlike PTFE and autogenous grafts. Prostacyclin (PGI2) effectively reduces platelet accumulation on Dacron grafts.
Area of Science:
- Biomedical Engineering
- Vascular Surgery
- Thrombosis Research
Background:
- Clinical vascular grafts like Dacron and expanded polytetrafluoroethylene (PTFE) are widely used.
- Understanding their in vivo platelet reactivity is crucial for preventing graft thrombosis.
- Autogenous artery grafts serve as a benchmark for biocompatibility.
Purpose of the Study:
- To compare the in vivo platelet reactivity of Dacron and PTFE grafts against autogenous artery grafts.
- To evaluate the effect of prostacyclin (PGI2) on platelet reactivity with these grafts.
Main Methods:
- Vascular grafts (Dacron, PTFE, autogenous) were implanted into baboon carotid arteries.
- Indium-111 labeled platelets were used to quantify graft platelet uptake via gamma camera scanning.
- Prostacyclin (PGI2) was administered to assess its anti-aggregating effects.
Main Results:
- Dacron grafts exhibited rapid and significant platelet accumulation post-implantation.
- PTFE and autogenous artery grafts showed comparable, minimal platelet uptake.
- Prostacyclin infusion prevented initial platelet uptake and reduced existing platelet activity on Dacron grafts.
Conclusions:
- Dacron grafts demonstrate higher in vivo platelet reactivity compared to PTFE and autogenous grafts.
- Prostacyclin (PGI2) effectively mitigates platelet accumulation on Dacron grafts, suggesting a potential therapeutic strategy.